Blamey R W, Bishop H M, Blake J R, Doyle P J, Elston C W, Haybittle J L, Nicholson R I, Griffiths K
Cancer. 1980 Dec 15;46(12 Suppl):2765-9. doi: 10.1002/1097-0142(19801215)46:12+<2765::aid-cncr2820461404>3.0.co;2-c.
For a minimum of 3- months, 250 women who underwent mastectomy for primary breast cancer have been followed up. ER status has had a pronounced effect upon disease-free interval and survival: in patients with node involvement ER-positive (ER+) tumors carry a better prognosis. Of patients with ER-positive primary tumors, 43% underwent objective response to their secondaries for a minimum period of six months. This compares with a response of only 18% for ER-negative (ER-) tumors. In patients who had previously received endocrine therapy and on relapse were treated with cytotoxic chemotherapy, objective response rate to chemotherapy was better in patients in whom the primary tumor had been ER-, but not significantly so.
至少3个月以来，对250名因原发性乳腺癌接受乳房切除术的女性进行了随访。雌激素受体（ER）状态对无病间期和生存率有显著影响：在有淋巴结受累的患者中，ER阳性（ER+）肿瘤的预后较好。在原发性肿瘤为ER阳性的患者中，43%的患者其转移灶出现了至少6个月的客观缓解。相比之下，ER阴性（ER-）肿瘤患者的缓解率仅为18%。在先前接受过内分泌治疗且复发后接受细胞毒性化疗的患者中，原发性肿瘤为ER阴性的患者对化疗的客观缓解率更高，但差异不显著。
